Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. Active clinical trials are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.
In this podcast, Timothy Gilligan, MD, FASCO, leads a discussion with Petros Grivas, MD, PhD; Sumanta (Monty) Pal, MD; and Tian Zhang, MD, about 3 clinical trials in prostate, bladder, and kidney cancer.
-
The TALAPRO-2 phase III clinical trial is testing whether using the combination of a PARP inhibitor drug with hormone therapy to treat people with metastatic castration-resistant prostate cancer delays cancer growth. [3:46]
-
The KEYNOTE-905 phase III clinical trial is studying whether treating localized muscle-invasive bladder cancer with immunotherapy before and after surgery to remove the bladder can successfully treat the disease or stop it from coming back. [8:40]
-
The COSMIC-313 phase III clinical trial is testing whether treating people who have poor-risk or intermediate-risk metastatic kidney cancer with a triplet combination of 2 immunotherapy drugs and a targeted therapy delays tumor growth. [17:15]
Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Pal is co-director of City of Hope's Kidney Cancer Program, the head of the kidney and bladder cancer disease team at the institution, and the Cancer.Net Associate Editor for Genitourinary Cancers. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine, an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an assistant professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers.
Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked in the paragraph above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.